DIABETIC KIDNEY DISEASE (SER150)

• Low Dose Anti-thromboxane Reduces Urinary Albumin in Patients with Diabetic Kidney Disease. Steiness E, Brun N, Skarsfeldt T and Derwahl K-M. Poster presentation at ASN Kidney Week, San Diego, CA, US, October 23-28, 2018.
• A Novel Surgery-induced Rat Model of Diabetic Nephropathy Displaying Progressive Albuminuria, Glomerular Hypertrophy and Glomerulosclerosis. Ostergaard MV, Johansen T, Secher T, Seebach FE, Rigbolt K, Skarsfeldt T, Vrang N, Fosgerau K and Fink LN. Poster presentation at ASN Kidney Week, San Diego, CA, US, October 23-28, 2018.
• The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer JP, Santana Sorensen A. J Thromb Haemost. 2011 Oct;9(10):2109-11. http://www.ncbi.nlm.nih.gov/pubmed/21777369
• EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin. Sakariassen KS, Femia EA, Daray FM, Podda GM, Razzari C, Pugliano M, Errasti AE, Armesto AR, Nowak W, Alberts P, Meyer JP, Sorensen AS, Cattaneo M, Rothlin RP. Thromb Res. 2012 Nov;130(5):746-52. http://www.ncbi.nlm.nih.gov/pubmed/22959706
• Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation. Richardson A, Sakariassen KS, Meyer JP, Alberts P, Sorensen AS. Eur J Clin Pharmacol. 2013 Mar;69(3):459-65. http://www.ncbi.nlm.nih.gov/pubmed/22815050
• Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells.Petri MH, Tellier C, Michiels C, Ellertsen I, Dogné JM, Bäck M. Biochem Biophys Res Commun. 2013 Nov 15;441(2):393-8. http://www.ncbi.nlm.nih.gov/pubmed/24161392
• Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. Rollini F, Tello-Montoliu A, Patel R, Darlington A, Wilson RE, Franchi F, Muñiz-Lozano A, Desai B, Bender N, Sakariassen KS, Angiolillo DJ. J Thromb Thrombolysis. 2014;37(2):131-8. http://www.ncbi.nlm.nih.gov/pubmed/23943337
• Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. Tello-Montoliu A, Rollini F, Desai B, Pasqualino G, Patel R, Sorensen AS, Sakariassen KS, Angiolillo DJ. J Thromb Thrombolysis. 2012 Oct;34(3):297-9. http://www.ncbi.nlm.nih.gov/pubmed/22923024

DIABETIC KIDNEY DISEASE (SER140)

• The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice. Helena Cucak,1 Gitte Hansen,1 Niels Vrang,1 Torben Skarsfeldt,2 Eva Steiness,2 and Jacob Jelsing1. http://www.hindawi.com/journals/jdr/2016/7484601/.
• Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. Boris Klementiev1, Shizhong Li1, Irina Korshunova1, Oksana Dmytriyeva1, Stanislava Pankratova1, Peter S Walmod1, Laura K Kjær2, Mattias S Dahllöf2, Morten Lundh2, Dan P Christensen2, Thomas Mandrup-Poulsen2,3, Elisabeth Bock1 and Vladimir Berezin1. http://www.biomedcentral.com/content/pdf/1742-2094-11-27.pdf

DIABETIC RETINOPATHY (SER130)

• Antiinflammatory properties of a peptide derived from interleukin-4. Boris Klementiev a, Maj N. Enevoldsen c, Shizhong Li a, Robert Carlsson b, Yawei Liu b, Shohreh Issazadeh-Navikas b, Elisabeth Bock a, Vladimir Berezin a, http://www.sciencedirect.com/science/article/pii/S1043466613006315